Actually, several VEGFR/PDGFR inhibitors are marketed for cancer therapy and have been exploited for the treatment of GBM and, among them, the indole derivative Sunitinib (Sutent, Pfizer) 1 (Chart 1), already approved in 2006 by the FDA for the treatment of renal cell carcinoma and gastrointestinal stromal tumor [14]. This evidence concerns the gene KDR and glioblastoma.